CLK1 and cancer: In addition, inhibited exon skipping of METTL14 and enhanced exon skipping of Cyclin L2 caused by CLK1’s enhancing SRSF5 SRSF5250-Ser phosphorylation enhanced the N6-methyladenosine modification level and cancer aggressiveness in pancreatic cancer [22].